Earnings · China A-shares
Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A (688076) earnings
Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A published its Q3 report on 2026-10-27: net profit -24.61% year on year, -14.89% excluding one-off items. Wave Radar's earnings-quality score is 100 of 100 (Sound). The stock moved -1.69% in the 3 trading days after the report.
- Report
- Q3 report
- Published
- 2026-10-27
- Period end
- 2026-09-30
- Net profit YoY
- -24.61%
- Excl. one-offs YoY
- -14.89%
- Net profit QoQ
- +40.29%
- Result
- Bad / loss
- Quality score
- 100
- Quality
- Sound
Stock move after the report
Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.
| After | Return | vs index |
|---|---|---|
| 1 day | +1.58% | — |
| 3 days | -1.69% | — |
| 7 days | +1.21% | — |
| 14 days | +1.25% | — |
Report history
Over the last 8 reports, net profit grew year on year in 4 of them. The stock rose in the 3 trading days after 3 of 6 reports (average +0.35%).
| Report | Published | Net profit | Profit YoY | Excl. one-offs YoY | Revenue YoY | EPS | ROE | 3 days after | 30 days after | 30d vs index |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 Q3 report | 2026-10-28 | ¥335.12M | -24.61% | -14.89% | +14.43% | 1.06 | 10.62% | -1.69% | — | — |
| 2026 interim report | 2026-08-26 | ¥215.05M | -30.64% | -18.60% | +8.72% | 0.68 | 6.95% | -1.36% | +0.72% | +7.71% |
| 2026 Q1 report | 2026-04-30 | ¥129.46M | -15.17% | -17.78% | -2.23% | 0.41 | 4.24% | +2.50% | -3.87% | -5.92% |
| 2025 annual report | 2026-04-30 | ¥332.42M | -17.80% | -10.21% | +19.57% | 1.06 | 11.47% | +2.50% | -3.87% | -5.92% |
| 2025 Q3 report | 2025-10-23 | ¥444.54M | +26.92% | +23.20% | +21.95% | 1.42 | 15.41% | +6.13% | +1.40% | +2.26% |
| 2025 interim report | 2025-08-21 | ¥310.05M | +36.49% | +33.49% | +26.07% | 0.99 | 11.03% | -7.98% | -12.95% | -23.63% |
| 2025 Q1 report | 2025-04-23 | ¥152.62M | +130.10% | +131.79% | +58.96% | 0.50 | 5.57% | +4.53% | +6.40% | +3.36% |
| 2024 annual report | 2025-04-23 | ¥404.39M | +148.19% | +142.60% | +57.21% | 1.34 | 16.96% | +4.53% | +6.40% | +3.36% |
The last 8 reports. Net profit is attributable to shareholders and year-to-date (a Q3 report covers the first nine months). Moves count trading days from the first tradeable session after publication; "30d vs index" is the excess return over CSI 300.
How to read this
Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.